Probiotics for vulvovaginal candidiasis in non-pregnant women

Xie, Huan; Feng, Dan; Dong, Wei; Chen, Hui; Mei, Ling; Wang, Xun; Fang, Fang

doi:10.1002/14651858.cd010496

Cited by 26 publications

(36 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent meta-analysis study suggested that, although probiotics appeared effective in treating VVC, relevant studies were not sufficient in number (5-7 studies included for each analysis) or of comparable quality (7). In the present study,…”

Section: Discussionmentioning

confidence: 55%

“…A meta-analysis by Huang et al (3) from 2014 indicated that probiotic supplementation improves the cure rate for BV. Other previously published systematic reviews have suggested that the use of probiotics remains controversial in preventing BV and VVC in adult females due to evidence limitations (4,6,7). Potential bias on the benefits of probiotics cannot be ruled out, as the majority of evidence came from small-scale studies, heterogeneous populations, different lengths of follow-up and inhomogeneous treatment designs among the study.…”

Section: Treating Vaginitis With Probiotics In Non-pregnant Females: mentioning

confidence: 99%

See 1 more Smart Citation

Treating vaginitis with probiotics in non‑pregnant females: A systematic review and meta‑analysis

2020

View full text Add to dashboard Cite

Vaginitis, also known as vulvovaginitis, is an inflammation of the vagina and vulva and a common disease in females. It is thought to be caused by vaginal dysbiosis and improved by probiotics. Bacterial vaginosis (BV) and vulvovaginal candidiasis (VVC) are the major types of vaginal infections. The present systematic review and meta-analysis aimed to clarify the efficacy of probiotics in the treatment of common vaginal infections in non-pregnant females. Literature on randomized controlled trials and two-armed prospective studies on any intervention with probiotics published until December 24th, 2018 was searched in the PubMed, Cochrane and EMBASE databases. The outcomes of interest were recurrence rate, cure rate, remission rate and normal vaginal flora restoration. Finally, a total of 30 studies on bacterial vaginosis (BV) and/or VVC were included and stratified into 3 study types based on treatment design as follows: Type I, antibiotic/probiotics vs. antibiotics/antifungals (22 studies); Type II, probiotics vs. placebo (5 studies); Type III, probiotics vs. antibiotics (3 studies). The type I studies comprised 1,788 non-pregnant females and had the highest inter-study comparability in post-treatment follow-up design and meta-analysis outcome data. Probiotics interventions were significantly associated with a lower recurrence rate of vaginitis [pooled odds ratio (OR)=0.27, 95% CI: 0.18-0.41, P<0.001] and higher cure/remission rate (pooled OR=2.28, 95% CI: 1.20-4.32, P= 0.011). However, a significant increase in normal vaginal flora after probiotic treatment was observed only in BV (pooled OR=4.55, 95% CI: 1.44-14.35, P=0.01). In addition, supportive but heterogeneous results were obtained from the 6-month follow-up data of Type-I studies, different infection types and supplementary analysis of Type-II studies. In conclusion, probiotics have a significant short-term effect in the treatment of common vaginal infections in non-pregnant females. In order to evaluate the long-term effects of probiotics in common vaginal infections, it is worthwhile to perform higher-quality clinical trials in the future.

show abstract

Section: Discussionmentioning

confidence: 55%

Section: Treating Vaginitis With Probiotics In Non-pregnant Females: mentioning

confidence: 99%

Treating vaginitis with probiotics in non‑pregnant females: A systematic review and meta‑analysis

2020

View full text Add to dashboard Cite

show abstract

“…Results from a review study 18 to the low quality of data available, there is insufficient evidence for the use of probiotics either as adjuvants to conventional antifungal medicines or used alone for the treatment of VVC in non-pregnant women. 20 In addition to lactobacilli, among a variety of natural substances, lactoferrin seems to be one of the most interesting compound for reducing the risk of vaginal candida infection. Lactoferrin is an iron-binding glycoprotein naturally present in mammals' secretions including milk and cervical mucus.…”

Section: Introductionmentioning

confidence: 99%

“…Adjunctive treatment does not seem to influence the rate of long‐term (within 1 to 3 months) clinical cure, long‐term mycological cure, serious and non‐serious side events. Up to the present, due to the low quality of data available, there is insufficient evidence for the use of probiotics either as adjuvants to conventional antifungal medicines or used alone for the treatment of VVC in non‐pregnant women …”

Section: Introductionmentioning

confidence: 99%

Randomised clinical trial in women with Recurrent Vulvovaginal Candidiasis: Efficacy of probiotics and lactoferrin as maintenance treatment

Russo¹,

Superti²,

Karadja

et al. 2019

Mycoses

View full text Add to dashboard Cite

Summary Background Vulvovaginal candidiasis (VVC) is a recurrent vaginal condition in childbearing women. Objectives The aim of this study was to assess the efficacy of an oral formulation containing Lactobacillus acidophilus GLA‐14, Lactobacillus rhamnosus HN001 and bovine lactoferrin on symptoms and recurrence of VVC as adjuvant therapy to topical clotrimazole. Patients/Methods Forty‐eight women positive for C. albicans, symptoms of VVC and documented history of recurrences were randomised into 2 groups receiving verum or placebo (2 capsules/day for 5 days followed by 1 capsule/day for additional 10 days) as adjuvant treatment to clotrimazole (induction phase) followed by a maintenance cycle of 6 months (1 capsule/day verum or placebo for 10 consecutive days each month). Symptoms, overall cure rate and recurrence rate were assessed. Results After clotrimazole therapy, a significant improvement of symptoms was shown in both groups. However, only women treated with probiotics and lactoferrin showed a significant improvement of itching and discharge at 3 and 6 months. During the six‐month follow‐up, recurrences were significantly less in the intervention group vs placebo (33.3% vs 91.7% after 3 months and 29.2% vs 100% after 6 months). Conclusions The results show that the investigated lactobacilli mixture in combination with lactoferrin represents a safe and effective adjuvant approach for reducing symptoms and recurrences of RVVC.

show abstract

“…However, the isolation and characterization of new probiotic strains are required for the development of new therapies [4]. Lactobacilli have been commonly used as probiotics for many years since they are easy to "select", cultivate and produce [5,6]. Moreover, the use of selected lactobacilli may be effective in restoring the vaginal microbiota and preventing infections [7].…”

Section: Introductionmentioning

confidence: 99%

In vitro characterization of Lactobacillus crispatus IP174178 and its live biotherapeutic product for prevention of vaginal infections

Dausset¹,

Daniel²,

Brami³

et al. 2019

Preprint

View full text Add to dashboard Cite

Background : Probiotics enhance human well-being. They can be used either as a preventive approach to maintain the microbiota or as an add-on treatment for some diseases. The lactobacilli constitute the predominant vaginal microorganism and have been associated with a beneficial effect in vaginal health by protecting and controlling the vaginal microbiota against bacterial vaginosis, vaginal candidiasis, and urinary tract infection. Results: We investigated the probiotic properties of the new vaginal Lactobacillus crispatus IP174178 strain isolated from healthy women. Lactobacillus crispatus IP174178 strain was identified by 16S rRNA sequencing and by biochemical characterization. L. crispatus IP174178 is Gram positive, Catalase negative, ADH negative, and an H 2 0 2 (5 mM) and lactic acid (D-lactate 6 g/l, L-lactate 3 g/l) producer, with a strong adherence capacity. Its sensitivity to antibiotics was evaluated. Conclusions: The native strain L. crispatus IP174178 showed natural antagonistic properties against vaginal pathogens ( Gardenerella vaginalis , Candida spp.) which is potentiated in its commercial live biotherapeutic product Physioflor ® . The L. crispatus IP174178 strain and its live biotherapeutic product Physioflor ® can thus be considered a good probiotic candidate for the prevention of vaginal infections.

show abstract

Probiotics for vulvovaginal candidiasis in non-pregnant women

Cited by 26 publications

References 48 publications

Treating vaginitis with probiotics in non‑pregnant females: A systematic review and meta‑analysis

Treating vaginitis with probiotics in non‑pregnant females: A systematic review and meta‑analysis

Randomised clinical trial in women with Recurrent Vulvovaginal Candidiasis: Efficacy of probiotics and lactoferrin as maintenance treatment

In vitro characterization of Lactobacillus crispatus IP174178 and its live biotherapeutic product for prevention of vaginal infections

Contact Info

Product

Resources

About